Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An update from Hightide Therapeutics Inc ( (HK:2511) ) is now available.
HighTide Therapeutics, Inc. announced positive results from two Phase III trials of HTD1801, demonstrating durable efficacy and safety over 52 weeks in treating type 2 diabetes mellitus (T2DM). The trials, SYMPHONY-1 and SYMPHONY-2, showed significant reductions in glycated hemoglobin (HbA1c) and maintained improvements in cardiometabolic and renal endpoints. The company plans to submit a new drug application for HTD1801 in China, highlighting its potential as a foundational therapy in CKM disease management.
More about Hightide Therapeutics Inc
HighTide Therapeutics, Inc. operates in the pharmaceutical industry, focusing on developing innovative therapies for cardiovascular-kidney-metabolic (CKM) diseases. Its primary product, HTD1801, is a first-in-class anti-inflammatory metabolic modulator designed to address metabolic dysfunctions.
Average Trading Volume: 1,337,693
Technical Sentiment Signal: Strong Buy
Current Market Cap: HK$1.93B
Learn more about 2511 stock on TipRanks’ Stock Analysis page.